GYM II STUDY (#16) 

Efficacy of the diabetic supplement Gymnemosupium II, a combination of the extracts of Gymnema sylvestre, Pterocarpus marsupium, Diachrome and Vanadium administered to patients with Type 2 diabetes.  

Materials and Methods 

Each capsule of Gymnemosupium II is a proprietary formulation of Gymnema sylvestre,  75% standardized extract, Pterocarpus marsupium, 5% standardized extract, Diachrome,  a combination of chromium picolinate and biotin, and vanadium in the form of bis-glycinate oxo vanadium (BVOG). 

Each Type II diabetic will receive a total of 8 capsules of Gymnemosupium II a day administered in a four dose a day regiment, 2 capsules will be taken immediately before breakfast, lunch, supper and evening snack. The dose of 8 capsules a day will be maintained by doubling a dose if necessary if an individual dose is missed. 

Trial will continue for a period of 90 days utilizing a total of 48 Type II diabetic subjects ranging in age between 30 to 60 years old and currently have a hemoglobin A1c>8.0. 

Subjects must be free of any type of renal complication and also not be consuming more than 200mcg of chromium or 1mg of vanadium daily. All participants will give written informed consent and continue their normal diet, exercise routine and doses of oral hypoglycemic and insulin. Two weeks prior and throughout the trial daily morning fasting and supper postprandial blood glucose will be monitored.   

Hemoglobin A1c will be taken before administration of the Gymnemosupium II and immediately upon the conclusion of the study. Body weight and blood pressure will also be monitored in the beginning and at the close of the trial. All oral hypoglycemic and insulin doses will be recorded as well. Adverse side effects, if any, will be noted.   

2 A1c tests will be provided to each patient and enough product for 90 days.  Each patient will be provided with 7- 2 week postage paid log books to be mailed in.    

Our Publisher, Steve Freed, R.Ph., was one of the presenters at a Friday morning symposium “New Chromium Combinations:  Improving Glucose and Cholesterol Control through Nutrition”

500 of your colleagues got up at 6 am to learn about chromium and diabetes and see some of the early data from the PEP study. We at DIABETES IN CONTROL were the main recruiters for the study and the preliminary results that those of you who chose to participate have provided were discussed. Mean Fasting Blood Glucose, in 70 participants with an average age of 54.3 dropped 25.2%, from 155mg/dl to 116.2 mg/dl in 90 days. Mean Post Prandial Glucose in that same group dropped 27.3% from 205.5 to 149.14.  We will have more on this next week.  

The same product DiaChrome is included in the Gym II study.

You can view the presentation using DiaChrome at:

Powerpoint presentation for Preliminary Results of PEP

If you are interested in having your patients participate, fill out the form.    

For More information on the Product, click Here